menu
    • menu
    [{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ITI-1001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immunomic Therapeutics \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Immunomic Therapeutics \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"HLB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"Dendritic cell vaccine therapy","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ HLB","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic Therapeutics \/ HLB"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Ichor Medical Systems","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"RBI-5000","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Replicate Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Immunomic Therapeutics \/ Replicate Bioscience"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ITI-1000","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"CoImmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1020","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Immunomic Therapeutics \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunomic Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Immunomic","highestDevelopmentStatusID":"1","companyTruncated":"Immunomic Therapeutics \/ Immunomic"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"PharmaJet","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ITI-1001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Immunomic Therapeutics

    Menu

    Immunomic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the T...

                            Details : ITI-1001 is an investigational plasmid DNA vaccine therapy that leverages Immunomic’s proprietary UNITE® platform to treat patients with newly diagnosed GBM.

                            Brand Name : ITI-1001

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 24, 2023

                            Lead Product(s) : ITI-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : PharmaJet

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaJet partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer

                            Details : ITI-3000 is an anticancer vaccine made by combining LAMP1 (lysosomal-associated membrane protein) with the large T antigen of polyomavirus based on Immunomic's cell therapy vaccine platform UNITE.

                            Brand Name : ITI-3000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : PharmaJet

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Lineage Cell Therapeutics

                            Deal Size : $69.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lineage Announces License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunother...

                            Details : The collaboration will generate a novel product candidate derived from Lineage’s VAC allogeneic cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by ITI, for the treatment of glioblastoma multif...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : $2.0 million

                            April 20, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Lineage Cell Therapeutics

                            Deal Size : $69.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-1020

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : CoImmune

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020

                            Details : ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (...

                            Brand Name : ITI-1020

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : ITI-1020

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : CoImmune

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics to Present at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annua...

                            Details : Immunomic Therapeutics will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mi...

                            Brand Name : ITI-3000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 02, 2020

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-1000,Tetanus and Diphtheria Toxoid vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ITI Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Trea...

                            Details : ITI is developing several dendritic cell vaccines for the treatment of cancer, including ITI-1000 for glioblastoma (GBM) that contains pp65-shLAMP mRNA DCs with GM-CSF, a dendritic cell vaccines for the treatment of cancer.

                            Brand Name : ITI-1000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : ITI-1000,Tetanus and Diphtheria Toxoid vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBI-5000

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Replicate Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Replicate Bioscience and Immunomic Therapeutics Form Collaboration

                            Details : ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV.

                            Brand Name : RBI-5000

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : RBI-5000

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Replicate Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-1001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Ichor Medical Systems

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation Deliver...

                            Details : ITI will leverage Ichor’s TriGrid® Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.

                            Brand Name : ITI-1001

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 16, 2020

                            Lead Product(s) : ITI-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Ichor Medical Systems

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II

                            Details : ITI-3000 is an innovative and novel targeted approach to a MCPγV vaccine. This lysosomal targeting technology results in enhanced antigen presentation and a balanced T cell response, as ITI-3000 activated antigen-specific CD4+ T cells in vivo.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 11, 2020

                            Lead Product(s) : ITI-3000

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Immunomic Therapeutics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dendritic cell vaccine therapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : HLB

                            Deal Size : $61.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics Announces Close of $61.3M Financing

                            Details : Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of its UNITE nucleic acid platform.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 23, 2020

                            Lead Product(s) : Dendritic cell vaccine therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : HLB

                            Deal Size : $61.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth